RESUMEN
Non-cutaneous melanomas (mucosal, uveal, leptomeningeal, unknown primaries) represent around 5-10 % of all melanoma diagnoses. Non-cutaneous melanomas demonstrate differences in tumour biology, generally present with more advanced stages and have an overall poorer prognosis compared to skin melanomas. The cornerstone of their treatment is surgery followed by radiotherapy in some cases. Unfortunately, in many of these patients their melanoma will recur. Adjuvant therapy for non-cutaneous melanomas remains controversial. To date, almost all of the tested adjuvant agents have failed to demonstrate any benefit; the two randomised positive trials were criticized for methodological reasons, small sample size and conflicting results. The aim of this review is to assess the current evidence on systemic adjuvant treatments for high-risk resected non-cutaneous melanomas. We also provide a summary table with the currently recruiting clinical trials in these settings and we discuss some strategies to improve trial design in this particularly niche area of oncology.
Asunto(s)
Melanoma , Neoplasias Cutáneas , Terapia Combinada , Humanos , Melanoma/tratamiento farmacológico , Membrana Mucosa , Neoplasias Cutáneas/tratamiento farmacológicoAsunto(s)
Denosumab/efectos adversos , Hipocalcemia/etiología , Insuficiencia Renal Crónica/tratamiento farmacológico , Anciano de 80 o más Años , Conservadores de la Densidad Ósea/efectos adversos , Conservadores de la Densidad Ósea/uso terapéutico , Calcio/uso terapéutico , Delirio/etiología , Delirio/fisiopatología , Denosumab/uso terapéutico , Humanos , Masculino , Insuficiencia Renal Crónica/fisiopatologíaRESUMEN
We present a case involving an 85-year-old man with acute confusion and new onset seizure following a 1-week history of respiratory prodrome. This case report describes a case of influenza B-related meningoencephalitis supported by evidence of an influenza B infection and temporal relation of the neurological event and respiratory illness in the absence of other identifiable cause. Diagnosis is guided by cerebrospinal fluid profile and nasopharyngeal PCR. Treatment is largely supportive and the effect of vaccination on prevention of this neurological complication remains unclear.
Asunto(s)
Antivirales/uso terapéutico , Betainfluenzavirus/aislamiento & purificación , Gripe Humana/diagnóstico , Gripe Humana/tratamiento farmacológico , Meningoencefalitis/virología , Anciano de 80 o más Años , Confusión/etiología , Humanos , Gripe Humana/líquido cefalorraquídeo , Betainfluenzavirus/genética , Levetiracetam , Masculino , Meningoencefalitis/líquido cefalorraquídeo , Meningoencefalitis/tratamiento farmacológico , Nasofaringe/virología , Piracetam/análogos & derivados , Piracetam/uso terapéutico , Convulsiones/tratamiento farmacológico , Convulsiones/etiología , Resultado del Tratamiento , Ácido Valproico/uso terapéuticoRESUMEN
The authors present a case involving an 80-year-old man with infectious T10/T11 discitis on the background of a recent Clostridium perfringens bacteraemia. This case report describes a case of probable C. perfringens discitis as further investigations failed to identify any causative agents. He was treated with intravenous piperacillin/tazobactam to good effect, achieving favourable clinical outcome. Diagnosis of discitis/osteomyelitis can often be delayed and mismanaged due to its non-specific presentations. Timing of empirical antimicrobial therapy requires careful consideration based on haemodynamic stability and neurological function to maximise microbiological yield.
